Ubs Group Ag Adaptimmune Therapeutics PLC Transaction History

Ubs Group Ag

  • $555 Billion
  • Q2 2025

A detailed history of Ubs Group Ag transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Ubs Group Ag holds 62,958 shares of ADAP stock, worth $16,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,958
Previous 1,012,740 93.78%
Holding current value
$16,369
Previous $202,000 92.57%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$0.22 - $0.32 $208,952 - $303,930
-949,782 Reduced 93.78%
62,958 $15,000
Q1 2025

May 13, 2025
BUY
$0.2 - $0.65 $174,199 - $566,147
870,996 Added 614.49%
1,012,740 $202,000
Q4 2024

Feb 14, 2025
BUY
$0.54 - $0.95 $75,560 - $132,930
139,927 Added 7700.99%
141,744 $76,000
Q2 2024

Aug 13, 2024
SELL
$0.83 - $1.47 $161,749 - $286,472
-194,879 Reduced 99.08%
1,817 $1,000
Q1 2024

May 13, 2024
BUY
$0.7 - $1.75 $120,402 - $301,005
172,003 Added 696.57%
196,696 $310,000
Q4 2023

Feb 09, 2024
SELL
$0.43 - $0.79 $1,565 - $2,876
-3,641 Reduced 12.85%
24,693 $19,000
Q3 2023

Nov 09, 2023
SELL
$0.73 - $1.04 $1,931 - $2,751
-2,646 Reduced 8.54%
28,334 $22,000
Q2 2023

Aug 11, 2023
BUY
$0.9 - $1.51 $3,807 - $6,387
4,230 Added 15.81%
30,980 $28,000
Q1 2023

May 12, 2023
BUY
$1.06 - $2.16 $3,312 - $6,750
3,125 Added 13.23%
26,750 $29,000
Q4 2022

Feb 08, 2023
BUY
$1.05 - $2.53 $22,723 - $54,751
21,641 Added 1090.78%
23,625 $34,000
Q3 2022

Nov 10, 2022
SELL
$1.06 - $2.41 $2,883 - $6,555
-2,720 Reduced 57.82%
1,984 $2,000
Q2 2022

Aug 10, 2022
SELL
$1.33 - $2.28 $1,048 - $1,796
-788 Reduced 14.35%
4,704 $8,000
Q1 2022

May 16, 2022
SELL
$1.73 - $4.06 $19,168 - $44,984
-11,080 Reduced 66.86%
5,492 $12,000
Q4 2021

Feb 14, 2022
BUY
$3.5 - $5.68 $3,734 - $6,060
1,067 Added 6.88%
16,572 $61,000
Q3 2021

Nov 15, 2021
BUY
$3.44 - $6.37 $5,479 - $10,147
1,593 Added 11.45%
15,505 $80,000
Q2 2021

Aug 13, 2021
SELL
$3.86 - $5.78 $672,303 - $1.01 Million
-174,172 Reduced 92.6%
13,912 $60,000
Q1 2021

May 12, 2021
BUY
$4.9 - $6.83 $31,859 - $44,408
6,502 Added 3.58%
188,084 $998,000
Q4 2020

Feb 11, 2021
BUY
$4.0 - $9.2 $224,996 - $517,490
56,249 Added 44.88%
181,582 $978,000
Q3 2020

Nov 12, 2020
BUY
$7.66 - $10.78 $959,514 - $1.35 Million
125,263 Added 178947.14%
125,333 $1 Million
Q2 2020

Jul 31, 2020
SELL
$2.58 - $12.1 $12,938 - $60,681
-5,015 Reduced 98.62%
70 $1,000
Q1 2020

May 01, 2020
SELL
$1.2 - $4.52 $1,370 - $5,161
-1,142 Reduced 18.34%
5,085 $14,000
Q4 2019

Feb 14, 2020
BUY
$0.72 - $1.43 $4,433 - $8,804
6,157 Added 8795.71%
6,227 $7,000
Q3 2019

Nov 14, 2019
SELL
$1.43 - $3.81 $11,482 - $30,594
-8,030 Reduced 99.14%
70 $0
Q2 2019

Aug 14, 2019
BUY
$3.23 - $5.41 $8,494 - $14,228
2,630 Added 48.08%
8,100 $32,000
Q1 2019

May 14, 2019
SELL
$3.63 - $6.06 $7,623 - $12,726
-2,100 Reduced 27.74%
5,470 $24,000
Q4 2018

Feb 14, 2019
SELL
$3.76 - $14.16 $414,570 - $1.56 Million
-110,258 Reduced 93.58%
7,570 $44,000
Q3 2018

Nov 14, 2018
BUY
$8.27 - $13.56 $878,025 - $1.44 Million
106,170 Added 910.71%
117,828 $1.6 Million
Q2 2018

Aug 14, 2018
BUY
$10.42 - $13.74 $85,735 - $113,052
8,228 Added 239.88%
11,658 $138,000
Q1 2018

May 15, 2018
SELL
$7.1 - $11.56 $17,515 - $28,518
-2,467 Reduced 41.83%
3,430 $38,000
Q4 2017

Feb 14, 2018
BUY
$6.68 - $8.74 $29,371 - $38,429
4,397 Added 293.13%
5,897 $39,000
Q3 2017

Nov 14, 2017
SELL
$4.93 - $8.93 $2,465 - $4,465
-500 Reduced 25.0%
1,500 $12,000
Q2 2017

Aug 14, 2017
BUY
N/A
1,228 Added 159.07%
2,000 $9,000
Q1 2017

Nov 14, 2017
BUY
N/A
772
772 $4,000

Others Institutions Holding ADAP

# of Institutions
70
Shares Held
116M
Call Options Held
10.3K
Put Options Held
0
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $42.5M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email